|
|
|
18.11.26 - 08:06
|
The last day of trading in warrants of series TO5 in Cell Impact is today, 18 November 2026 (Cision)
|
|
|
THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, PUBLICATION OR DISTRIBUTION OF THE INFORMATION WOULD NOT COMPLY WITH APPLICABLE RULES OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE ANY SECURITIES IN CELL IMPACT AB (PUBL). PLEASE ALSO SEE THE "IMPORTANT INFORMATION" SECTION BELOW. THIS PRESS RELEASE HAS...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17.11.26 - 14:03
|
Aevius Launches with $22 Million in Funding to Make Medicine Computable (Business Wire)
|
|
|
Mass General Brigham spinout backed by Insight Partners aims to turn fragmented patient data into insights that support better care and advance clinical researchBOSTON--(BUSINESS WIRE)--#Aevius--Aevius, the clinical intelligence company making medicine computable, today announced $22 million in funding led by Insight Partners. The financing will support continued model and product development, expansion of the company's engineering, clinical and commercial teams, and commercial deployment.Aevius develops AI models that learn from structured, unstructured, and specialty multimodal medical data. They turn the information healthcare, payer and life sciences organizations hold into intelligence their teams and AI tools can act on. Applications span healthcare delivery, operations and life sciences.Aevius was founded by Rowland Pettit, Ming Yang (Max) Lu, Faisal Mahmood and Long Phi Le - part of the founding team behind Modella AI, which was acquired by AstraZeneca. The founders are now applying their experie...
|
|
|
|
|
|
|
|
|
|
|
|
|
|